Patents by Inventor Shabbir T. Anik

Shabbir T. Anik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pegylated carfilzomib compounds
    Patent number: 11077198
    Abstract: The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: August 3, 2021
    Assignee: AMGEN INC.
    Inventors: Gary Luehr, Shabbir T. Anik, Ge Peng, Irina Dotsenko, Pasit Phiasivongsa, Dante Romanini
  • Pegylated Carfilzomib Compounds
    Publication number: 20200376131
    Abstract: The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.
    Type: Application
    Filed: April 23, 2020
    Publication date: December 3, 2020
    Applicant: AMGEN INC.
    Inventors: Gary LUEHR, Shabbir T. ANIK, Ge PENG, Irina DOTSENKO, Pasit PHIASIVONGSA, Dante ROMANINI
  • Prodrugs of peptide epoxy ketone protease inhibitors
    Patent number: 10682419
    Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 16, 2020
    Assignee: ONYX THERAPEUTICS, INC.
    Inventors: Pasit Phiasivongsa, Gary W. Luehr, Ge Peng, Kolbot By, Shabbir T. Anik
  • Pegylated carfilzomib compounds
    Patent number: 10675353
    Abstract: The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: June 9, 2020
    Assignee: AMGEN INC.
    Inventors: Gary Luehr, Shabbir T. Anik, Ge Peng, Irina Dotsenko, Pasit Phiasivongsa, Dante Romanini
  • PEGYLATED CARFILZOMIB COMPOUNDS
    Publication number: 20200069808
    Abstract: The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.
    Type: Application
    Filed: November 5, 2019
    Publication date: March 5, 2020
    Inventors: Gary LUEHR, Shabbir T. ANIK, Ge PENG, Irina DOTSENKO, Pasit PHIASIVONGSA, Dante ROMANINI
  • Pegylated carfilzomib compounds
    Patent number: 10517954
    Abstract: The present invention provides polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein. The invention also provides methods of making and using these compounds to treat cancer, and particularly to treat hematological malignancies including multiple myeloma.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: December 31, 2019
    Assignee: Amgen Inc.
    Inventors: Gary Luehr, Shabbir T. Anik, Ge Peng, Irina Dotsenko, Pasit Phiasivongsa, Dante Romanini
  • PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS
    Publication number: 20180147291
    Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.
    Type: Application
    Filed: January 29, 2018
    Publication date: May 31, 2018
    Inventors: Pasit Phiasivongsa, Gary W. Luehr, Ge Peng, Kolbot By, Shabbir T. Anik
  • Prodrugs of peptide epoxy ketone protease inhibitors
    Patent number: 9878047
    Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: January 30, 2018
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Pasit Phiasivongsa, Gary W. Luehr, Ge Peng, Kolbot By, Shabbir T. Anik
  • PEGYLATED CARFILZOMIB COMPOUNDS
    Publication number: 20170340746
    Abstract: The present invention provides polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein. The invention also provides methods of making and using these compounds to treat cancer, and particularly to treat hematological malignancies including multiple myeloma.
    Type: Application
    Filed: May 23, 2017
    Publication date: November 30, 2017
    Inventors: Gary LUEHR, Shabbir T. ANIK, Ge PENG, Irina DOTSENKO, Pasit PHIASIVONGSA, Dante ROMANINI
  • PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS
    Publication number: 20160263234
    Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.
    Type: Application
    Filed: March 9, 2016
    Publication date: September 15, 2016
    Inventors: Pasit Phiasivongsa, Gary W. Luehr, Ge Peng, Kolbot By, Shabbir T. Anik
  • Prodrugs of peptide epoxy ketone protease inhibitors
    Patent number: 9315542
    Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.
    Type: Grant
    Filed: September 30, 2013
    Date of Patent: April 19, 2016
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Pasit Phiasivongsa, Gary Luehr, Ge Peng, Kolbot By, Shabbir T. Anik
  • Prodrugs of peptide epoxy ketone protease inhibitors
    Patent number: 9309283
    Abstract: Provided herein are compounds of formula (I): which are pro-drugs of epoxy ketone protease inhibitors. The compounds disclosed herein include one or more moieties that (i) confer enhanced solubility, permeability, pharmacokinetics, and/or pharmacodynamics properties to epoxy ketone protease inhibitors, and (ii) can be released in vivo. Also provided herein are pharmaceutical compositions of the compounds of formula (I), and methods of using the compounds of formula (I) to treat diseases and conditions.
    Type: Grant
    Filed: July 9, 2013
    Date of Patent: April 12, 2016
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Pasit Phiasivongsa, Gary W. Luehr, Ge Peng, Kolbot By, Shabbir T. Anik
  • Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
    Publication number: 20140105921
    Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.
    Type: Application
    Filed: July 9, 2013
    Publication date: April 17, 2014
    Inventors: Pasit Phiasivongsa, Gary Luehr, Ge Peng, Kolbot By, Shabbir T. Anik
  • Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
    Publication number: 20140100154
    Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.
    Type: Application
    Filed: September 30, 2013
    Publication date: April 10, 2014
    Applicant: Onyx Therapeutics, Inc.
    Inventors: Pasit Phiasivongsa, Gary Luehr, Ge Peng, Kolbot By, Shabbir T. Anik
  • Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
    Publication number: 20140100168
    Abstract: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.
    Type: Application
    Filed: July 9, 2013
    Publication date: April 10, 2014
    Inventors: Pasit Phiasivongsa, Gary Luehr, Ge Peng, Kolbot By, Shabbir T. Anik
  • Spray plume characterization system
    Publication number: 20030098968
    Abstract: The density of a spray plume generated by an aerosol delivery system (“ADS”) may be characterised by illuminating a face of the plume with light and then imaging the plume. The shape of the plume may be characterised by operating the ADS in a controlled manner to form a first spray plume. A face of the plume is illuminated and the plume imaged from a first side parallel to the spray axis of the plume. The ADS is then again operated in the controlled manner to form a second spray plume. A face of the second plume is illuminated and the second plume imaged from a second side which is parallel to the spray axis of the plume and perpendicular to the first side.
    Type: Application
    Filed: November 26, 2001
    Publication date: May 29, 2003
    Applicant: Patheon Inc.
    Inventors: Steve Y.T. Yang, Anthony Y. Qu, Shabbir T. Anik
  • LHRH preparations for intranasal administration
    Patent number: 5116817
    Abstract: The present invention relates to a novel nasal composition comprising a nona- or decapeptide having LHRH agonist or antagonist activity and a surfactant which is a bile acid or a pharmaceutically acceptable salt thereof in a buffered aqueous solution.
    Type: Grant
    Filed: September 20, 1990
    Date of Patent: May 26, 1992
    Assignee: Syntex (U.S.A.) Inc.
    Inventor: Shabbir T. Anik
  • Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
    Patent number: 4476116
    Abstract: Disclosed herein are nasal spray compositions and methods for enhancing polypeptide absorption across nasal membranes comprising a chelating agent and a polypeptide in a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: December 10, 1982
    Date of Patent: October 9, 1984
    Assignee: Syntex (U.S.A.) Inc.
    Inventor: Shabbir T. Anik